Genome-Wide Association Study of Circulating Estradiol, Testosterone, and Sex Hormone-Binding Globulin in Postmenopausal Women

Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.
PLoS ONE (Impact Factor: 3.23). 06/2012; 7(6):e37815. DOI: 10.1371/journal.pone.0037815
Source: PubMed


Genome-wide association studies (GWAS) have successfully identified common genetic variants that contribute to breast cancer risk. Discovering additional variants has become difficult, as power to detect variants of weaker effect with present sample sizes is limited. An alternative approach is to look for variants associated with quantitative traits that in turn affect disease risk. As exposure to high circulating estradiol and testosterone, and low sex hormone-binding globulin (SHBG) levels is implicated in breast cancer etiology, we conducted GWAS analyses of plasma estradiol, testosterone, and SHBG to identify new susceptibility alleles. Cancer Genetic Markers of Susceptibility (CGEMS) data from the Nurses' Health Study (NHS), and Sisters in Breast Cancer Screening data were used to carry out primary meta-analyses among ~1600 postmenopausal women who were not taking postmenopausal hormones at blood draw. We observed a genome-wide significant association between SHBG levels and rs727428 (joint β = -0.126; joint P = 2.09 × 10(-16)), downstream of the SHBG gene. No genome-wide significant associations were observed with estradiol or testosterone levels. Among variants that were suggestively associated with estradiol (P<10(-5)), several were located at the CYP19A1 gene locus. Overall results were similar in secondary meta-analyses that included ~900 NHS current postmenopausal hormone users. No variant associated with estradiol, testosterone, or SHBG at P<10(-5) was associated with postmenopausal breast cancer risk among CGEMS participants. Our results suggest that the small magnitude of difference in hormone levels associated with common genetic variants is likely insufficient to detectably contribute to breast cancer risk.

Download full-text


Available from: Immaculata De Vivo, Oct 08, 2015
17 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Mammographic breast density and endogenous sex-hormone levels are both strong risk factors for breast cancer. This study investigated whether there is evidence for a shared genetic basis between these risk factors. METHODS: Using data on 1286 women from 617 families we estimated the heritabilities of serum estradiol, testosterone and sex-hormone binding globulin (SHBG) levels and of three measures of breast density (dense area, non-dense area and percent density). We tested for associations between hormone levels and density measures, and estimated the genetic and environmental correlations between pairs of traits using variance and co-variance components models and pedigree-based maximum likelihood methods. RESULTS: We found no significant associations between estradiol, testosterone or SHBG levels and any of the three density measures, after adjusting for BMI. The estimated heritabilities were 63%, 66% and 65% for square-root transformed adjusted percent-density, dense area and non-dense area respectively, and 40%, 25% and 58% for log-transformed adjusted estradiol, testosterone and SHBG. We found no evidence of a shared genetic basis between any hormone levels and any measure of density, after adjusting for BMI. The negative genetic correlation between dense and non-dense areas remained significant even after adjustment for BMI and other covariates (p=-0.34, se=0.08, P=0.0005). Conclusions and Impact: Breast density and sex hormones can thus be considered as independent sets of traits, each of which can be used as intermediate phenotypes in the search for breast cancer susceptibility loci.
    Cancer Epidemiology Biomarkers & Prevention 10/2012; 21(12). DOI:10.1158/1055-9965.EPI-12-0789 · 4.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Even though the levels of circulating sex steroid hormones are to a large extent heritable, their genetic determinants are largely unknown. With the advent of genome-wide association studies (GWAS), much progress has been made and several genetic loci have been identified to be associated with serum levels of dehydroepiandrosterone sulfate, testosterone and sex hormone-binding globulin. The variants identified so far only explain a small amount of the overall heritability, but may help to elucidate the role of sex steroid hormones in common disorders such as hypogonadism, type 2 diabetes and hormone-sensitive cancers. This review provides an overview of the current state of knowledge of the genetic determinants of sex steroid hormones, with a focus on recent GWAS and brief directions for elucidating the remaining heritability.
    Molecular and Cellular Endocrinology 03/2013; 382(1). DOI:10.1016/j.mce.2013.03.009 · 4.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The study of large prospective collections of plasma samples from women prior to the development of breast cancer has firmly established certain sex steroids as being significantly associated with risk. The strongest associations have been found in postmenopausal women in whom the within person variability of most hormones is markedly reduced but some positive associations have also been seen in premenopausal women. Plasma estrogens show the strongest correlations with risk and these are strengthened by measurement or calculation of the proportion of estradiol that circulates free of sex hormone binding globulin (SHBG), consistent with this being the most active fraction. The relationships have been reported to potentially explain virtually all of the association of breast cancer with body mass index in postmenopausal women; this is likely to be due to non-ovarian estrogen synthesis being prominent in subcutaneous fat. These strong relationships have led to plasma and urine estrogen levels being used as intermediate end-points in the search for genes that affect breast cancer risk via their role in steroid disposition. Plasma androgen levels also show a relationship with breast cancer risk that is weakened but not eliminated by ‘correction’ for estrogen levels. This has been argued to be evidence of the local production of estrogens being important in the etiology of breast cancer. Given that plasma steroid levels do not correlate closely with mammographic density, which is strongly associated with risk, the opportunity exists to combine the two factors in assessing breast cancer risk but the low availability of suitable estrogen assays is a major impediment to this. In established breast cancer, plasma estrogens have been found to correlate with gene expression of estrogen dependent genes and the expression of these varies across the menstrual cycle of premenopausal women.
    Breast (Edinburgh, Scotland) 08/2013; 22S2:S38-S43. DOI:10.1016/j.breast.2013.07.007 · 2.38 Impact Factor
Show more